Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

MLA

Moyle, Graeme, et al. “Switching to Dolutegravir plus Rilpivirine versus Maintaining Current Antiretroviral Therapy Regimen in Virologically Suppressed People with HIV-1 and the Lys103Asn (K103N) Mutation: 48-Week Results from a Randomised, Open-Label Pilot Clinical Trial.” The Lancet. HIV, vol. 11, no. 3, Mar. 2024, pp. e156–66. EBSCOhost, https://doi.org/10.1016/S2352-3018(23)00292-8.

APA

Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., Masia, M., Vera, J., Jones, B., Grove, R., Fletcher, C., Duffy, A., Morris, K., & Pozniak, A. (2024). Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial. The Lancet. HIV, 11(3), e156–e166. https://doi.org/10.1016/S2352-3018(23)00292-8

Chicago

Moyle, Graeme, Lambert Assoumou, Nathalie de Castro, Frank A Post, Adrian Curran, Stefano Rusconi, Stephane De Wit, et al. 2024. “Switching to Dolutegravir plus Rilpivirine versus Maintaining Current Antiretroviral Therapy Regimen in Virologically Suppressed People with HIV-1 and the Lys103Asn (K103N) Mutation: 48-Week Results from a Randomised, Open-Label Pilot Clinical Trial.” The Lancet. HIV 11 (3): e156–66. doi:10.1016/S2352-3018(23)00292-8.